A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo

被引:1
|
作者
Peng, Jingyi [1 ,2 ]
Wu, Jiaguo [2 ,3 ]
Shi, Ning [2 ,4 ]
Xu, Hua [2 ]
Luo, Longlong [2 ]
Wang, Jing [2 ]
Li, Xinying [2 ]
Xiao, He [2 ]
Feng, Jiannan [2 ]
Li, Xia [1 ]
Chai, Lihui [1 ]
Qiao, Chunxia [2 ,5 ]
机构
[1] Henan Univ, Affiliated Hosp 1, Sch Med, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China
[2] Acad Mil Med Sci, Acad Mil Med Sci, Inst Pharmacol & Toxicol, State key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China
[3] Dali Univ, Sch Basic Med Sci, Dept Anat, Dalian, Peoples R China
[4] Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Peoples R China
[5] Henan Univ, Sch Pharm, Kaifeng, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
abrin; humanization; neutralizing antibody; protective effect; computer-aided design; RIBOSOME-INACTIVATING PROTEINS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; RICIN; PROTECTION; TOXIN;
D O I
10.3389/fimmu.2022.831536
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Abrin, a type-II ribosome inactivating protein from the seed of Abrus precatorius, is classified as a Category B bioterrorism warfare agent. Due to its high toxicity, ingestion by animals or humans will lead to death from multiple organ failure. Currently, no effective agents have been reported to treat abrin poisoning. In this study, a novel anti-abrin neutralizing antibody (S008) was humanized using computer-aided design, which possessed lower immunogenicity. Similar to the parent antibody, a mouse anti-abrin monoclonal antibody, S008 possessed high affinity and showed a protective effect against abrin both in vitro and in vivo, and protected mice that S008 was administered 6 hours after abrin. S008 was found that it did not inhibit entry of abrin into cells, suggesting an intracellular blockade capacity against the toxin. In conclusion, this work demonstrates that S008 is a high affinity anti-abrin antibody with both a neutralizing and protective effect and may be an excellent candidate for clinical treatment of abrin poisoning.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential
    Liu, Xiaolei
    Han, Jianzhong
    Wang, Qian
    Wang, Peng
    Li, Li
    Du, Kehe
    Jiang, Fengchao
    Zhang, Pei
    Liu, Hongjun
    Huang, Jian
    ANTIBODY THERAPEUTICS, 2024, 7 (02) : 123 - 130
  • [32] Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition
    Amiri, Mohammad Mehdi
    Golsaz-Shirazi, Forough
    Soltantoyeh, Tahereh
    Hosseini-Ghatar, Reza
    Bahadori, Tannaz
    Khoshnoodi, Jalal
    Navabi, Shadi Sadat
    Farid, Samira
    Karimi-Jafari, Mohammad Hossein
    Jeddi-Tehrani, Mahmood
    Shokri, Fazel
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 171 - 186
  • [33] A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo
    Lei, Gaoxin
    Xu, Menglong
    Xu, Zhipan
    Gu, Lili
    Lu, Chenchen
    Bai, Zhengli
    Wang, Yue
    Zhang, Yongbo
    Hu, Huajing
    Jiang, Yiwei
    Zhao, Wenfeng
    Tan, Shuhua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [34] Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models
    Shiravi, Fariba
    Mohammadi, Mehdi
    Golsaz-Shirazi, Forough
    Bahadori, Tannaz
    Judaki, Mohammad Ali
    Fatemi, Forough
    Zare, Hengameh Ahmadi
    Haghighat, Farzaneh Notash
    Mobini, Maryam
    Jeddi-Tehrani, Mahmood
    Amiri, Mohammad Mehdi
    Shokri, Fazel
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 697 - 704
  • [35] An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression
    Walter, Miriam
    Simanovich, Elina
    Brod, Vera
    Lahat, Nitza
    Bitterman, Haim
    Rahat, Michal A.
    ONCOIMMUNOLOGY, 2016, 5 (02):
  • [36] Design and Construction of a Novel Humanized Single-Chain Variable- Fragment Antibody Against the Tumor Necrosis Factor Alpha
    Farajzadeh, Davoud
    Karimi-Gharigh, Sadigheh
    Jalali-Kondori, Parisa
    Dastmalchi, Siavoush
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (01): : 308 - 319
  • [37] Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma
    Shinriki, Satoru
    Jono, Hirofumi
    Ota, Kazutoshi
    Ueda, Mitsuharu
    Kudo, Mareina
    Ota, Tomoko
    Oike, Yuichi
    Endo, Motoyoshi
    Ibusuki, Mutsuko
    Hiraki, Akimitsu
    Nakayama, Hideki
    Yoshitake, Yoshihiro
    Shinohara, Masanori
    Ando, Yukio
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5426 - 5434
  • [38] In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity
    Phoolcharoen, Waranyoo
    Banyard, Ashley C.
    Prehaud, Christophe
    Selden, David
    Wu, Guanghui
    Birch, Colin P. D.
    Szeto, Tim H.
    Lafon, Monique
    Fooks, Anthony R.
    Ma, Julian K-C
    VACCINE, 2019, 37 (33) : 4673 - 4680
  • [39] Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma
    Zhang, Haifeng
    Song, Liping
    Ye, Hongtu
    Hu, Lide
    Liang, Wenlu
    Liu, Datao
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2013, 32 (03) : 645 - 654
  • [40] Structure and Functional Characterization of a Humanized Anti-CCL20 Antibody following Exposure to Serum Reveals the Formation of Immune Complex That Leads to Toxicity
    Thomson, Andrew S.
    Mai, Shing H.
    Bouma, Gerben
    Herdman, Michael
    Byrne, Michael
    Hottenstein, Charles S.
    Minetti, Joseph
    Trulli, Stephen
    Taylor, J. David
    White, John R.
    Chen, Shugui
    JOURNAL OF IMMUNOLOGY, 2021, 206 (05) : 1067 - 1076